Investment Rating - The report assigns an "Outperform" rating for the industry, indicating a relative performance better than the benchmark index [2][4]. Core Insights - The pharmaceutical sector experienced a mild rebound, with the SW Pharmaceutical Biotechnology Index increasing by 0.50%, ranking 25th out of 31 in the primary industry indices. Notably, the medical consumables and other biological products sectors performed well, while CXO and chemical preparations lagged [2]. - Chinese innovation in ADC (Antibody-Drug Conjugates) was highlighted at the ASCO GU 2026 conference, showcasing promising clinical data for DB-1311 in metastatic castration-resistant prostate cancer, with a median radiographic progression-free survival (rPFS) of 11.3 months and a median overall survival (mOS) of 22.5 months [2]. - The success of the second-phase clinical trial for UBT251, a long-acting GLP-1/GIP/GCG tri-target agonist, was reported, showing an average weight loss of 19.7% in participants after 24 weeks of treatment. The company plans to initiate phase three clinical trials soon [2]. Summary by Sections Industry Performance - The A-share pharmaceutical sector's performance was subdued, with a 1.08% increase in the Shanghai and Shenzhen 300 Index during the week following the Spring Festival. The medical consumables sector saw a notable increase of 3.99% [2]. Clinical Developments - At the ASCO GU 2026 conference, over 70 research outcomes from Chinese experts were presented, with significant updates from several companies on ADC therapies, indicating a strong potential for ADC combined with immunotherapy in first-line cancer treatments [2]. - The report emphasizes the importance of ADCs, dual antibodies, small nucleic acids, and weight-loss drugs as key investment opportunities in the pharmaceutical sector [2]. Investment Recommendations - The report suggests that despite recent market fluctuations and a downturn in Hong Kong's innovative drug sector, the long-term trend of innovation in China's pharmaceutical industry remains positive. It highlights the potential for investment in ADCs, dual antibodies, and other high-growth areas [2].

Core Viewpoint - The article emphasizes the importance of creating and realizing "certainty" for Limited Partners (LPs) and establishing a safety margin for projects in the biopharmaceutical sector, which is currently experiencing a structural recovery rather than a full cycle breakthrough [2][14]. Group 1: Market Dynamics - The Chinese primary market is showing signs of recovery after a prolonged period of stagnation, particularly in the biopharmaceutical sector, with significant BD transaction amounts and IPO activities in Hong Kong [3][6]. - Despite the positive developments, many small and medium-sized enterprises continue to face financing challenges and intense competition in research and development [3][4]. - The average cost of developing a new drug exceeds $2 billion, with a timeline of over ten years, leading to high uncertainty in the process [6][10]. Group 2: Investment Challenges - The investment cycle mismatch poses a structural challenge, necessitating General Partners (GPs) to adopt more systematic and proactive strategies to address LPs' needs for visible returns [7][10]. - The urgency for exits has intensified, with many funds entering exit periods while traditional IPO exits are growing slowly, leading to a demand for alternative exit strategies [10][11]. Group 3: Innovative Solutions - An innovative exit strategy involving "layered exits + value sharing + cycle matching" has been proposed to address LPs' urgent exit needs while allowing original LPs to retain some equity for future gains [11][15]. - The proactive management approach aims to provide LPs with clear exit pathways and support the growth of invested companies [11][14]. Group 4: Long-term Investment Strategy - The article highlights the importance of long-term investment strategies, with firms like Xingze Capital focusing on early-stage investments even during market downturns, resulting in impressive DPI metrics and high renewal rates [15][18]. - The success of investments in innovative drug companies is attributed to a combination of deep involvement in the early stages, strategic planning, and facilitating business development partnerships [21][22]. Group 5: Future Outlook - The year 2026 is anticipated to be a critical juncture for Chinese biopharmaceutical companies and investment institutions, with the need for GPs to create and realize value for LPs becoming increasingly pressing [7][25]. - The ability to navigate the long cycles and high risks in the industry will determine which firms can successfully create value and plan for the future [26].

Industry Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Outperform the Market" [1] Core Insights - The surgical robot industry is expected to see accelerated development due to the introduction of standardized pricing policies, marking a significant policy breakthrough in China [4][15] - The report highlights key beneficiaries in the surgical robot sector, including Tianzhihang and MicroPort, which are positioned to benefit from the new pricing framework [5][18] - The overall performance of the pharmaceutical and biotechnology sector has shown a slight increase, with a 0.5% rise in A-share pharmaceutical stocks, although it underperformed compared to the CSI 300 index [20][21] Summary by Sections 1. Surgical Robot Industry - The National Healthcare Security Administration released a guideline establishing a unified pricing framework for surgical robots and related technologies, which is expected to enhance clinical penetration and application in hospitals [4][15] - The pricing model categorizes surgical robots based on their participation and clinical value, promoting the use of high-value robots in complex surgeries [15][16] 2. Beneficiary Companies - Key beneficiaries include Tianzhihang, which is expected to transition from a one-time equipment sales model to a sustainable model involving equipment, consumables, and services [16][17] - MicroPort has demonstrated strong global capabilities and product diversification, with significant commercial orders for its surgical robots [18] 3. Market Performance - The A-share pharmaceutical sector rose by 0.5% from February 23 to February 27, 2026, ranking 25th among 31 sub-industries [20][21] - The medical consumables sector performed the best within the pharmaceutical sub-sectors, with a 3.99% increase, while the medical research outsourcing sector saw a decline of 2.2% [21] 4. Investment Opportunities - The report suggests focusing on companies with high certainty and low disruption expectations, such as Innovent Biologics and 3SBio, as well as new technology sectors like small nucleic acids [24][25] - The report also emphasizes the potential for growth in the CXO and life science service sectors due to stable demand recovery in overseas research and production outsourcing [25] 5. AI in Healthcare - AI technology is enhancing drug development efficiency and success rates, with companies leveraging AI for molecular design and drug screening [36][37] - The report identifies four key areas where AI is expected to benefit healthcare companies, including AI in pharmaceuticals, imaging/surgery, auxiliary diagnosis, and healthcare services [37]

Industry Overview - The Chinese automotive industry has seen weaker-than-expected performance in the first two months for new energy vehicles, with a focus on the upcoming new car releases in March to drive demand recovery [2] - Li Auto's February delivery volume decreased by only 5% month-on-month to approximately 26,000 units, outperforming most peers, primarily due to the contribution from the i6 model launched in September 2025 [2] - NIO's February delivery volume fell by 23% month-on-month to about 21,000 units, with the NIO brand contributing approximately 15,000 units [2] - XPeng's February delivery volume decreased by 24% month-on-month to around 15,000 units, falling short of expectations, with a cumulative year-on-year decline of 42% for January and February [2] Sales Forecast - The forecast for February 2026 indicates a 15% month-on-month decline in retail sales of new energy passenger vehicles to approximately 480,000 units, with a year-on-year decline of 23% for January and February [6] - The market share of new energy vehicles is expected to drop to around 40% following a reduction in purchase tax incentives starting January 2026, but is anticipated to rebound starting in March with the release of new models [6] Company Insights - NIO is expected to face challenges in 2026 due to a faster-than-expected decline in orders for new models, despite achieving its first non-GAAP net profit in Q4 2025 [5] - BYD's wholesale sales of passenger vehicles in February fell by 9% month-on-month to approximately 188,000 units, with a cumulative year-on-year decline of 36% for January and February [5] - Geely's new energy vehicle sales, including the Zeekr brand, increased by 10% year-on-year in the first two months of 2026, supported by positive market feedback for new models [5] - Leap Motor's February wholesale sales decreased by 12% month-on-month to about 28,000 units, with a cumulative year-on-year decline of 19% for January and February [5] AI in Pharmaceutical Industry - The MSCI China Healthcare Index has risen by 5.0% since early 2026, outperforming the MSCI China Index by 6.2%, despite a recent pullback in the pharmaceutical sector [6] - AI is expected to significantly change the paradigm of innovative drug development, with rapid advancements in AI applications within the pharmaceutical industry [7] - Major global pharmaceutical companies are increasingly privatizing and upgrading their core AI infrastructure to build high data barriers [7] - The launch of LillyPod by Eli Lilly, equipped with NVIDIA technology, exemplifies the integration of AI in clinical development and manufacturing processes [7] Company Recommendations - Recommended stocks include 3SBio (1530 HK), JAC (1167 HK), Genscript (2273 HK), WuXi AppTec (2268 HK), and China Biologic Products (1177 HK) [9]

Core Viewpoint - Fosun International (00656.HK) announced a share buyback plan with a total amount not exceeding HKD 1 billion, citing that the current stock price does not reflect the company's long-term value and expressing confidence in its future development [1] Group 1: Business Performance - In 2026, Fosun's core sectors, including biomedicine, cultural tourism, and insurance, continue to show strong momentum [2] - The biopharmaceutical sector has made significant strides, with a partnership with Eisai Co., Ltd. for H drug Hansai in Japan, potentially worth over USD 300 million, and a global exclusive licensing agreement with Pfizer valued at over USD 2 billion [2] - In cultural tourism, Fosun's various product lines have performed well, with Shanghai Yuyuan receiving nearly 1.2 million visitors during the Spring Festival, a year-on-year increase of over 20%, and Atlantis Sanya achieving a record revenue of RMB 124 million during the holiday, up 20% year-on-year [2] Group 2: Insurance Sector Growth - Fosun's domestic insurance companies reported significant growth in 2025, with Fosun United Health Insurance achieving revenue of RMB 7.84 billion, a 50% increase, and Fosun Puhui Life Insurance reporting revenue of RMB 12.598 billion, a 36.17% increase, with net profit soaring over 450% to RMB 647 million [3] - The robust growth in core businesses is seen as a catalyst for the share buyback, with improved asset structure and clear growth logic justifying a more reasonable market valuation [3] Group 3: Share Buyback Details - Fosun International previously repurchased 13.027 million shares for HKD 48.2354 million on February 27, and has cumulatively repurchased 258.859 million shares since January 1, 2022, accounting for 3.17% of total issued shares, with a total expenditure of approximately HKD 1.19 billion [3] - The announcement emphasized that the buyback aligns with the overall interests of the company and its shareholders at the current valuation level [4]

Investment Rating - The report maintains a positive outlook on the innovative drug sector, highlighting multiple favorable developments and collaborations within the industry [1]. Core Insights - The innovative drug sector has seen significant collaborations, with a total business development (BD) value exceeding $50 billion in the first two months of 2026, indicating a robust growth trajectory [16]. - The report emphasizes the upcoming Q2 conferences (AACR, ELCC, ASCO, EHA) as potential catalysts for stock price increases in innovative drug companies due to expected positive data releases [16]. - The report identifies a strong performance in the medical consumables sub-sector, which has shown a 4.0% increase, while the best-performing sectors year-to-date include hospitals, medical consumables, and offline pharmacies [21][27]. Summary by Sections 1. Investment Strategy - The pharmaceutical index rose by 0.50% this week, underperforming the CSI 300 index by 0.58 percentage points, ranking 26th in industry performance [13]. - Year-to-date, the pharmaceutical sector has increased by 2.96%, outperforming the CSI 300 index by 1.21 percentage points, ranking 24th [21]. - The current valuation level (PE-TTM) for the pharmaceutical industry is 31.06 times, with a premium of 66.99% over the entire A-share market [23]. 2. Industry and Company News - Frontier Biotech has entered a global licensing agreement with GSK for small nucleic acid drugs, with a total potential value of $963 million, including an upfront payment of $40 million [14]. - Bai Li Tianheng's dual-target antibody ADC, iza-bren, has successfully met primary endpoints in a Phase III trial for triple-negative breast cancer (TNBC), indicating significant progress in this high-risk area [15]. - The report notes that several innovative drug companies have issued profit forecasts, suggesting a sustained interest and potential growth in the sector [16]. 3. Steady Portfolio - Recommended stocks include Heng Rui Medicine (600276), Bai Jie Shen Zhou-U (688235), Yi Fan Medicine (002019), and others, indicating a diversified approach to investment in the pharmaceutical sector [16][17].

Group 1: Industry Investment Rating - The investment rating for the overseas social services industry is positive, with a focus on the record-high visitor numbers during the Macau Spring Festival [6]. Group 2: Core Insights - The total number of inbound visitors to Macau during the Spring Festival reached 1.554 million, with an average daily visitor count of 173,000, marking a year-on-year increase of 5.5% [6][1]. - Among the inbound visitors, mainland tourists averaged 134,000 per day, reflecting a 7% year-on-year growth, while international visitors averaged nearly 7,900 per day, up by 8% [6][1]. - The hotel occupancy rate during the Spring Festival was 95.6%, with the highest rate of 99.2% recorded on the fourth day of the festival [6][1]. Group 3: Summary by Relevant Sections Overseas Pharmaceuticals - The report highlights significant developments in the pharmaceutical sector, including the announcement of clinical trial results for B7-H3 ADC by Yingensheng and the completion of Phase II trials for UBT251 by Lianbang Pharmaceutical [3][10]. - In 2025, BeiGene reported revenues of $5.343 billion, a 40% increase year-on-year, while adjusted net profits reached $917 million, marking a return to profitability [9][21]. - The report also notes that the average weight loss in the UBT251 trial was as high as 19.7% after 24 weeks, compared to a 2.0% loss in the placebo group [11][10]. Overseas Education - The vocational education sector is experiencing an upswing, with promising enrollment data, particularly for China Oriental Education [5][17]. - The education index saw a decline of 4.9% in the recent week, underperforming the Hang Seng National Enterprises Index by 2.1 percentage points [15]. - The report recommends focusing on China Oriental Education, which is expected to see accelerated enrollment growth due to its strategic adjustments in response to market demands [17][15].

Investment Rating - The report maintains an "Overweight" rating for the overseas consumer services sector, indicating a positive outlook for the industry [1]. Core Insights - The total visitor volume and average daily visitor volume in Macau during the Spring Festival reached historical highs, with total inbound travelers at 1.554 million and an average daily volume of 173,000, reflecting a year-on-year growth of 5.5% [6][1]. - The average hotel occupancy rate during the Spring Festival in Macau was 95.6%, peaking at 99.2% on the fourth day of the festival [6][1]. - In the overseas pharmaceutical sector, companies like BeiGene and Zai Lab are showing significant revenue growth, with BeiGene projected to achieve $5.343 billion in revenue for 2025, a 40% increase year-on-year [9][2]. Summary by Sections Overseas Consumer Services - Macau's Spring Festival saw a record total of 1.554 million inbound travelers, with a daily average of 173,000, marking a 5.5% increase year-on-year [6][1]. - The peak single-day visitor count reached approximately 228,000, the highest since records began [6][1]. - Hotel occupancy rates averaged 95.6%, with the highest rate of 99.2% on the fourth day of the festival [6][1]. Overseas Pharmaceuticals - BeiGene reported a revenue of $5.343 billion for 2025, a 40% increase from the previous year, and an adjusted net profit of $917 million, marking a return to profitability [9][2]. - Zai Lab is expected to achieve $460 million in revenue for 2025, a 15% year-on-year increase, despite a net loss of $176 million [9][2]. - The report highlights the progress of domestic pharmaceutical companies, including the efficacy results of Innovent Biologics' B7-H3 ADC in treating metastatic castration-resistant prostate cancer [10][3]. Education Sector - The report indicates a positive trend in vocational education, with significant enrollment data and a recommendation to focus on China Oriental Education, which is expected to see accelerated growth in spring 2026 [18][5]. - The education index has shown a year-to-date increase of 6.01%, outperforming the Hang Seng Index [16][5]. - The report suggests monitoring companies like New Oriental and TAL Education, which are expected to benefit from improved operational strategies and increased demand for vocational training [18][5].

Group 1 - The report indicates that the current geopolitical tensions between the US and Iran are expected to have a short-term impact on the A-share market, with a focus on technology and cyclical sectors as the main investment themes [2][24][25] - Historical analysis shows that after previous conflicts involving Iran, sectors such as defense, non-ferrous metals, and oil & petrochemicals tend to perform well in the immediate aftermath, but the impact diminishes over time [2][28][29] - The report suggests that the upcoming National People's Congress (NPC) in China may lead to supportive policies for technology and cyclical sectors, which could benefit from the current geopolitical climate [2][24][25] Group 2 - The report highlights that the technology and cyclical sectors are expected to remain the main focus for investment in the short term, driven by rising commodity prices and government policies aimed at boosting domestic demand [2][24][28] - It is noted that the AI industry and military technology are expected to provide strong support for technology growth despite potential negative impacts from rising oil prices and a stronger dollar [2][24][25] - The report emphasizes that the profitability trends for technology and cyclical sectors are likely to improve, supported by positive policy directions and high-quality development initiatives [2][24][25]

Investment Rating - The report does not explicitly state an investment rating for the industry or specific companies Core Insights - The report highlights that China's innovative drug development is experiencing high-quality growth, significantly outpacing the global average, establishing China as a key player in global innovative drug research and development [11] - The medical device sector is seeing a recovery in bidding scale, with a positive outlook for domestic companies as they expand internationally [11] - The CXO and raw material drug sectors are expected to benefit from a recovering financing environment and increasing demand, indicating a potential new wave of growth in the innovative drug supply chain [11] - The report emphasizes the importance of AI and brain-machine interface technologies in driving industry transformation [11] Market Review - The report notes that the CITIC pharmaceutical index rose by 0.41%, underperforming the CSI 300 index by 0.67 percentage points, ranking 24th among 30 primary industries [8] - The top ten stocks by growth this week include Aidi Te, Koyuan Pharmaceutical, and Duorui Pharmaceutical, while the bottom ten include Zexing Pharmaceutical and Meihua Medical [8] Industry and Stock Events - The report discusses the strong performance of innovative drugs, medical devices, and the CXO sector, suggesting a focus on companies like Bai Li Tianheng, Bai Ji Shen Zhou, and Hengrui Medicine for potential investment opportunities [11] - It also highlights the recovery of the blood products industry, with a clear growth path expected during the 14th Five-Year Plan period [11] Company-Specific Insights - Lonza is projected to achieve a revenue growth of 11%-12% in 2026, with a strong performance in its CDMO business [14] - Samsung Biologics anticipates a revenue growth of 15%-20% for 2026, driven by strong demand and new contracts [41] - Medpace expects its revenue to grow by 8.9%-12.8% in 2026, focusing on biotech clients [100]